Corporate VCs crowd into $43M round for Celladon FierceBiotech The money will be used to engineer late-stage work on Mydicar, a heart failure treatment that recently gained fast-track status at the FDA. It also marks a major milestone for Celladon, which announced five years ago that it had raised $30 million from ... Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for ... |
